<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02511990</url>
  </required_header>
  <id_info>
    <org_study_id>MCA-0885</org_study_id>
    <nct_id>NCT02511990</nct_id>
  </id_info>
  <brief_title>A Study of the Safety, Pharmacokinetics and Antiretroviral Activity of 10-1074</brief_title>
  <official_title>A Phase 1, Open Label, Dose-escalation Study of the Safety, Pharmacokinetics and Antiretroviral Activity of 10-1074 Monoclonal Antibody in HIV-infected and HIV-uninfected Individuals</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rockefeller University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Cologne</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Rockefeller University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase 1 clinical trial to evaluate the safety, pharmacokinetics and the&#xD;
      antiretroviral effects of the highly neutralizing anti-HIV-1 monoclonal antibody 10-1074 in&#xD;
      HIV-infected and HIV-uninfected individuals.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In preclinical studies carried out in humanized mice and non-human primates, 10-1074 alone or&#xD;
      in combination with other neutralizing antibodies led to protection from HIV or simian/human&#xD;
      immunodeficiency virus (SHIV) infection and also to sustained suppression of HIV plasma&#xD;
      viremia. The aims of this protocol are to evaluate the safety, tolerability and&#xD;
      pharmacokinetics profile of 10-1074 in both HIV-infected and HIV-uninfected individuals, and&#xD;
      its antiretroviral activity in HIV-infected individuals.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2015</start_date>
  <completion_date type="Actual">December 2017</completion_date>
  <primary_completion_date type="Actual">December 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with Adverse Events as a Measure of Safety and Tolerability</measure>
    <time_frame>24 weeks after 10-1074 administration</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum peak concentration of 10-1074, measured in micrograms per ml</measure>
    <time_frame>24 hours after 10-1074 administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum half-life of 10-1074 expressed in days</measure>
    <time_frame>24 Weeks after 10-1074 administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma HIV-1 RNA levels measured in copies/ml</measure>
    <time_frame>2 weeks after 10-1074 administration</time_frame>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Actual">33</enrollment>
  <condition>Healthy</condition>
  <condition>HIV</condition>
  <arm_group>
    <arm_group_label>Group 1A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HIV-infected individuals Off ART, HIV-1 viral load &lt; 100,000 copies/ml or On ART, HIV-1 viral load &lt; 500 copies/ml&#xD;
3 mg/kg, single dose IV administration of 10-1074</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 1B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HIV-infected individuals Off ART, HIV-1 viral load &lt; 100,000 copies/ml or On ART, HIV-1 viral load &lt; 500 copies/ml&#xD;
10 mg/kg, single dose IV administration of 10-1074</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 1C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HIV-infected individuals Off ART, HIV-1 viral load &lt; 100,000 copies/ml or On ART, HIV-1 viral load &lt; 500 copies/ml&#xD;
30 mg/kg, single dose IV administration of 10-1074</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 1D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HIV-infected individuals Off ART, HIV-1 viral load &lt; 100,000 copies/ml&#xD;
30 mg/kg, single dose IV administration of 10-1074</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HIV-uninfected individuals&#xD;
3 mg/kg, single dose IV administration of 10-1074</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HIV-uninfected individuals&#xD;
10 mg/kg, single dose IV administration of 10-1074</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HIV-uninfected individuals&#xD;
30 mg/kg, single dose IV administration of 10-1074</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HIV-uninfected individuals&#xD;
30 mg/kg, single dose IV administration of 10-1074</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>3 mg/kg, single dose IV administration of 10-1074</intervention_name>
    <description>3 mg/kg, single dose IV administration of 10-1074</description>
    <arm_group_label>Group 1A</arm_group_label>
    <arm_group_label>Group 2A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>10 mg/kg, single dose IV administration of 10-1074</intervention_name>
    <description>10 mg/kg, single dose IV administration of 10-1074</description>
    <arm_group_label>Group 1B</arm_group_label>
    <arm_group_label>Group 2B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>30 mg/kg, single dose IV administration of 10-1074</intervention_name>
    <description>30 mg/kg, single dose IV administration of 10-1074</description>
    <arm_group_label>Group 1C</arm_group_label>
    <arm_group_label>Group 1D</arm_group_label>
    <arm_group_label>Group 2C</arm_group_label>
    <arm_group_label>Group 2D</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Group 1 (HIV-infected)&#xD;
&#xD;
          -  Males and females, age 18 to 65&#xD;
&#xD;
          -  HIV-1 infection confirmed by two independent assays.&#xD;
&#xD;
          -  Group (1A-1C): HIV-infected individuals off ART for at least 8 weeks with HIV-1 plasma&#xD;
             RNA levels &lt; 100,000 copies/ml by standard assays, or on ART with HIV-1 plasma RNA&#xD;
             levels &lt; 500 copies/ml. HIV-1 RNA levels should be measured on 2 occasions, at least 1&#xD;
             week apart and one measurement must be performed within 49 days prior to enrollment.&#xD;
&#xD;
          -  Group (1D): HIV-infected individuals off ART for at least 8 weeks with HIV-1 plasma&#xD;
             RNA levels &lt; 100,000 copies/ml by standard assays, measured on 2 occasions, at least 1&#xD;
             week apart. At least one measurement must be performed within 49 days prior to&#xD;
             enrollment.&#xD;
&#xD;
          -  Current CD4 count &gt; 300 cells/μl.&#xD;
&#xD;
          -  If sexually active male or female, and participating in sexual activity that could&#xD;
             lead to pregnancy, agrees to use two effective methods of contraception from 10 days&#xD;
             prior to the 10-1074 infusion until the end of the study.&#xD;
&#xD;
        Group 2 (HIV-uninfected):&#xD;
&#xD;
          -  Males and females, age 18 to 65.&#xD;
&#xD;
          -  Amenable to HIV risk reduction counseling and agrees to maintain behavior consistent&#xD;
             with low risk of HIV exposure.&#xD;
&#xD;
          -  If sexually active male or female, and participating in sexual activity that could&#xD;
             lead to pregnancy, agrees to use two effective methods of contraception throughout the&#xD;
             study period, as described for the HIV-infected groups above.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Group 1 (HIV-infected):&#xD;
&#xD;
          -  Have a history of AIDS-defining illness within 1 year prior to enrollment.&#xD;
&#xD;
          -  History of systemic corticosteroids, immunosuppressive anti-cancer, or other&#xD;
             medications considered significant by the trial physician within the last 6 months.&#xD;
&#xD;
          -  Any clinically significant acute or chronic medical condition other than HIV&#xD;
             infection, that in the opinion of the investigator would preclude participation.&#xD;
&#xD;
          -  Chronic Hepatitis B or Hepatitis C infection.&#xD;
&#xD;
          -  Laboratory abnormalities in the parameters listed below:&#xD;
&#xD;
        Absolute neutrophil count ≤ 1,000; Hemoglobin ≤10 gm/dL; Platelet count ≤100,000; ALT ≥ 2.0&#xD;
        x ULN; AST ≥ 2.0 x ULN; Total bilirubin ≥ 1.25 x ULN; Creatinine ≥ 1.1 x ULN; Coagulation&#xD;
        parameters (PT, PTT or INR) ≥ 1.25 x ULN.&#xD;
&#xD;
          -  Pregnancy or lactation.&#xD;
&#xD;
          -  Any vaccination within 14 days prior to 10-1074 administration.&#xD;
&#xD;
          -  History of severe reaction to a vaccine or drug infusion or history of severe allergic&#xD;
             reactions.&#xD;
&#xD;
          -  Participation in another clinical study of an investigational product currently or&#xD;
             within past 12 weeks, or expected participation during this study.&#xD;
&#xD;
        Group 2 (HIV-uninfected):&#xD;
&#xD;
          -  Confirmed HIV-1 or HIV-2 infection.&#xD;
&#xD;
          -  History of immunodeficiency or autoimmune disease; use of systemic corticosteroids,&#xD;
             immunosuppressive anti-cancer, or other medications considered significant by the&#xD;
             trial physician within the last 6 months.&#xD;
&#xD;
          -  Any clinically significant acute or chronic medical condition (such as autoimmune&#xD;
             diseases) that in the opinion of the investigator would preclude participation.&#xD;
&#xD;
          -  Within the 12 months prior to enrollment, the volunteer has a history of sexually&#xD;
             transmitted infection.&#xD;
&#xD;
          -  Chronic Hepatitis B or Hepatitis C infection.&#xD;
&#xD;
          -  Laboratory abnormalities in the parameters listed:&#xD;
&#xD;
        Absolute neutrophil count ≤ 1,500; Hemoglobin ≤ 12 gm/dL if female; ≤ 13.5 gm/dL if male;&#xD;
        Platelet count ≤ 140,000; Alanine transaminase (ALT) ≥ 1.25 x upper limit of normal (ULN);&#xD;
        aspartate transaminase (AST) ≥ 1.25 x ULN; Total bilirubin ≥ 1.25 x ULN; Creatinine ≥ 1.1 x&#xD;
        ULN; Coagulation parameters (prothrombin time - PT, partial thromboplastin time - PTT or&#xD;
        INR) ≥ 1.25 x ULN.&#xD;
&#xD;
          -  Pregnancy or lactation.&#xD;
&#xD;
          -  Any vaccination within 14 days prior to 10-1074 administration.&#xD;
&#xD;
          -  Receipt of any experimental HIV vaccine in the past.&#xD;
&#xD;
          -  History of severe reaction to a vaccine or drug infusion or history of severe allergic&#xD;
             reactions.&#xD;
&#xD;
          -  Participation in another clinical study of an investigational product currently or&#xD;
             within past 12 weeks, or expected participation during this study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marina Caskey, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rockefeller University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Rockefeller University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Cologne</name>
      <address>
        <city>Cologne</city>
        <zip>50937</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <study_first_submitted>July 24, 2015</study_first_submitted>
  <study_first_submitted_qc>July 28, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 30, 2015</study_first_posted>
  <last_update_submitted>January 31, 2018</last_update_submitted>
  <last_update_submitted_qc>January 31, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV</keyword>
  <keyword>10-1074</keyword>
  <keyword>Monoclonal Antibody</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

